Applying AI to Discover Drivers of Response to 
Immune Checkpoint Inhibitors
Recording Access

On June 23, 2020, the GNS team was joined by Craig Davis, Sr. Director of Translational Oncology at Pfizer, to discuss the use of our AI platform for identifying drivers of immune checkpoint inhibitor response. We covered how companies leading the charge on ICI development are faced with many questions including:

  1. What are the molecular drivers of tumor response?
  2. What biomarkers, in addition to the currently approved ones, better identify the subset of patients who see clinical benefit from ICI therapy for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC)?
  3. How can we turn non-responsive tumors (cold) into responsive tumors (hot)?

Access the recording by filling out the form to the right. 



Craig Davis, PhD
Senior Director of Translational Oncology

Rahul Das

Rahul Das, PhD
Associate Director of Precision Medicine
GNS Healthcare

Ellen Gordon

Ellen Gordon, PhD
Principal, Client Solutions
GNS Healthcare